Search for notes by fellow students, in your own course and all over the country.
Browse our notes for titles which look like what you need, you can preview any of the notes via a sample of the contents. After you're happy these are the notes you're after simply pop them into your shopping cart.
Title: Kotter’s Change Model (Step 7 and 8) in Genetic Testing in Chronic Pain Patients
Description: Genetic Testing in Chronic Pain Patients Stage 7 & 8 Standard pain medications need activation by the CYP2D6 enzyme to become effective. Roughly half of patients possess genes that alter the function of the CYP2D6 enzyme. Testing for the gene alterations allows the physician to make changes to the dosage regimens so as to cater for the altered metabolisms, which optimizes the efficacy and safety of pain medications.
Description: Genetic Testing in Chronic Pain Patients Stage 7 & 8 Standard pain medications need activation by the CYP2D6 enzyme to become effective. Roughly half of patients possess genes that alter the function of the CYP2D6 enzyme. Testing for the gene alterations allows the physician to make changes to the dosage regimens so as to cater for the altered metabolisms, which optimizes the efficacy and safety of pain medications.
Document Preview
Extracts from the notes are below, to see the PDF you'll receive please use the links above
Running head: GENETIC TESTING IN CHRONIC PAIN
Genetic Testing in Chronic Pain Patients Stage 7 & 8
Name
Institution
Date
1
GENETIC TESTING IN CHRONIC PAIN
2
Kotter’s Change Model (Step 7 and 8) in Genetic Testing in Chronic Pain Patients
Standard pain medications need activation by the CYP2D6 enzyme to become
effective
...
Testing for the gene alterations allows the physician to make changes to the dosage
regimens so as to cater for the altered metabolisms, which optimizes the efficacy and safety
of pain medications
...
The Kotter stage 7 insists on resistance and
interdependence as the major topics
...
Resistance will be eminent and expected until the change is registered in the organization’s
culture
...
The program was implemented as the first step and gained enormous benefits for the
patient and the physicians
...
This kind or argument could lead to a reduction of urgency,
momentum and funding as attention moves to other programs will lower resistance
...
As more significant changes are introduced into the system, more people and
resources or subprojects will need to be added
...
To produce more change, the chronic
GENETIC TESTING IN CHRONIC PAIN
3
pain management program will require both tactical and strategic vision for efficient delivery
...
Remember simplicity in
maximizing work not done and evaluate the changes or additions to the system to ensure you
address only issues that address the vision of reducing chronic pain for patients
...
A declaration that success has been achieved in the chronic
pain management program would lead to loss of urgency before the changes are deeply
planted in the organization’s culture
...
The desired vision should be pursued in this stage until the
change is permanently taken up as part of the organization’s culture and is reflected in the
values and norms
...
This ensures that even when the pressure related to change effort is
withdrawn, the change remains in rooted in the organization’s culture, values and norms
...
For
example, physicians get more quality time with other patients when chronic pain is
effectively managed
...
GENETIC TESTING IN CHRONIC PAIN
4
References
Green, J
...
6 Keys to L6S: Professor John P
...
Phytel,
Dallas, Texas, USA
...
phytel
...
(2015)
...
Kotter International, Cambridge,
Massachusetts, USA
...
kotterinternational
Title: Kotter’s Change Model (Step 7 and 8) in Genetic Testing in Chronic Pain Patients
Description: Genetic Testing in Chronic Pain Patients Stage 7 & 8 Standard pain medications need activation by the CYP2D6 enzyme to become effective. Roughly half of patients possess genes that alter the function of the CYP2D6 enzyme. Testing for the gene alterations allows the physician to make changes to the dosage regimens so as to cater for the altered metabolisms, which optimizes the efficacy and safety of pain medications.
Description: Genetic Testing in Chronic Pain Patients Stage 7 & 8 Standard pain medications need activation by the CYP2D6 enzyme to become effective. Roughly half of patients possess genes that alter the function of the CYP2D6 enzyme. Testing for the gene alterations allows the physician to make changes to the dosage regimens so as to cater for the altered metabolisms, which optimizes the efficacy and safety of pain medications.